Abstract

Case Report

Novel Complication of Nusinersen Treatment: Hyponatremia

Yasemin Coban*

Published: 15 October, 2018 | Volume 3 - Issue 1 | Pages: 020-022

There are variations in therapeutic regimens of different liver diseases. The accurate diagnosis ensNusinersen treatment is a novel therapy for spinal muscular atrophy (SMA) type 1; consequently, the adverse reactions of the therapy, have not been well known, yet. The present study is a case report that declares a hyponatremia development after the nursinersen therapy. Since the therapy is quite new one and has limited practice, we hope that this rare complication will contribute to the scientific literature.

Read Full Article HTML DOI: 10.29328/journal.jcicm.1001014 Cite this Article Read Full Article PDF

References

  1. Biogen Inc. SPINRAZA (nusinersen) injection, for intrathecal use: US prescribing information. 2016; Ref.: https://goo.gl/DjKjoi
  2. Spinraza (nusinersen) Prescribing Information. Cambridge, MA: Biogen, 2017;
  3. Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017; 81: 355–368. Ref.: https://goo.gl/rewjnT
  4. Claborn MK, Stevens DL, Walker CK, Gildon B. Nusinersen in the Treatment of Spinal Muscular Atrophy. Methods Mol Biol. 2018; 1828: 69-76. Ref.: https://goo.gl/esiVFr
  5. Ottesen EW. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci. 2017; 8: 1–6. Ref.: https://goo.gl/thWsps
  6. Hoy SM. Nusinersen: first global approval. Drugs2017; 77: 473-479. Ref.: https://goo.gl/kZD3Cu
  7. Safety Team Leader Review. NDA 209531. Spinraza (nusinersen). Benefit-Risk Summary and Assessment. Center for Drug Evaluatıon And Research. Reference ID: 4028770.
  8. Jones DP. Syndrome of Inappropriate Secretion of Antidiuretic Hormone and Hyponatremia. Pediatr Rev 2018; 39: 27-35. Ref.: https://goo.gl/VPgG1i

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More